- Home
- KLTR vs BEATW Comparison
KLTR vs BEATW Comparison
Compare KLTR & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTR
- BEATW
- Stock Information
- Founded
- KLTR 2006
- BEATW 2015
- Country
- KLTR United States
- BEATW United States
- Employees
- KLTR N/A
- BEATW 20
- Industry
- KLTR EDP Services
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- KLTR Technology
- BEATW Technology
- Exchange
- KLTR Nasdaq
- BEATW Nasdaq
- Market Cap
- KLTR N/A
- BEATW N/A
- IPO Year
- KLTR 2021
- BEATW N/A
- Fundamental
- Price
- KLTR $1.92
- BEATW $0.51
- Analyst Decision
- KLTR Buy
- BEATW
- Analyst Count
- KLTR 3
- BEATW 0
- Target Price
- KLTR $2.83
- BEATW N/A
- AVG Volume (30 Days)
- KLTR 366.4K
- BEATW 4.7K
- Earning Date
- KLTR 05-07-2025
- BEATW 03-14-2025
- Dividend Yield
- KLTR N/A
- BEATW N/A
- EPS Growth
- KLTR N/A
- BEATW N/A
- EPS
- KLTR N/A
- BEATW N/A
- Revenue
- KLTR $178,717,000.00
- BEATW N/A
- Revenue This Year
- KLTR $3.36
- BEATW N/A
- Revenue Next Year
- KLTR $3.79
- BEATW N/A
- P/E Ratio
- KLTR N/A
- BEATW N/A
- Revenue Growth
- KLTR 2.02
- BEATW N/A
- 52 Week Low
- KLTR $0.76
- BEATW $0.50
- 52 Week High
- KLTR $2.82
- BEATW $0.62
- Technical
- Relative Strength Index (RSI)
- KLTR 44.37
- BEATW N/A
- Support Level
- KLTR $1.84
- BEATW N/A
- Resistance Level
- KLTR $2.18
- BEATW N/A
- Average True Range (ATR)
- KLTR 0.12
- BEATW 0.00
- MACD
- KLTR 0.02
- BEATW 0.00
- Stochastic Oscillator
- KLTR 33.33
- BEATW 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.